---
figid: PMC3713377__IJCB2013-973584.002
figlink: /pmc/articles/PMC3713377/figure/fig2/
number: Figure 2
caption: Schematic of HER-2 structure, activation, and signalling. (a) HER-2 is a
  single transmembrane cell surface receptor with extracellular, transmembrane, and
  intracellular regions. The extracellular region comprises of two ligand-binding
  domains (L I and L II) and two cysteine-rich domains (C I and C II) []. Intracellularly,
  HER-2 receptors have intrinsic tyrosine kinase activity (TK). (b) HER-2 does not
  bind ligands but is activated by forming heterodimers with other ErbB receptors
  via interaction at the cysteine-rich domains. This results in autophosphorylation
  of the tyrosine kinase domains and induction of downstream signalling. Normal signalling
  includes stimulation of the PI3K/AKT pathway which induces survival mechanisms and
  inhibits apoptosis, whilst the RAS/RAF/MEK/MAPK pathway stimulates cell proliferation
  [].
pmcid: PMC3713377
papertitle: Clinical Significance of HER-2 Splice Variants in Breast Cancer Progression
  and Drug Resistance.
reftext: Claire Jackson, et al. Int J Cell Biol. 2013;2013:973584.
pmc_ranked_result_index: '4922'
pathway_score: 0.596961
filename: IJCB2013-973584.002.jpg
figtitle: HER-2 structure, activation, and signalling
year: '2013'
organisms: Homo sapiens
ndex: ae906d28-df36-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3713377__IJCB2013-973584.002.html
  '@type': Dataset
  description: Schematic of HER-2 structure, activation, and signalling. (a) HER-2
    is a single transmembrane cell surface receptor with extracellular, transmembrane,
    and intracellular regions. The extracellular region comprises of two ligand-binding
    domains (L I and L II) and two cysteine-rich domains (C I and C II) []. Intracellularly,
    HER-2 receptors have intrinsic tyrosine kinase activity (TK). (b) HER-2 does not
    bind ligands but is activated by forming heterodimers with other ErbB receptors
    via interaction at the cysteine-rich domains. This results in autophosphorylation
    of the tyrosine kinase domains and induction of downstream signalling. Normal
    signalling includes stimulation of the PI3K/AKT pathway which induces survival
    mechanisms and inhibits apoptosis, whilst the RAS/RAF/MEK/MAPK pathway stimulates
    cell proliferation [].
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MAPK1
  - MAP2K2
  - PIK3R5
  - MAPK14
  - C2
  - HRAS
  - ERBB2
  - EGF
  - AKT2
  - KRAS
  - NRAS
  - MAPK13
  - MAPK12
  - RAF1
  - AKT3
  - PIK3R6
  - MAPK8
  - MAP2K1
  - MAPK3
  - MAPK9
  - MAPK10
  - PIK3R3
  - BRAF
  - ARAF
  - AKT1
  - PIK3R4
  - MAPK11
  - PIK3CD
  - PIK3CG
  - PIK3CB
  - PIK3CA
  - Tyrosine
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: CII
  symbol: C2
  source: hgnc_symbol
  hgnc_symbol: C2
  entrez: '717'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: HER-2
  symbol: HER-2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: EGF
  symbol: EGF
  source: hgnc_symbol
  hgnc_symbol: EGF
  entrez: '1950'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
chemicals:
- word: Tyrosine
  source: MESH
  identifier: D014443
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
---
